The Centers for Disease Control and Prevention (CDC) has confirmed one case of monkeypox in a Massachusetts man who had recently traveled to Canada. Another patient in New York City has tested positive for orthopoxvirus, the family of viruses to which monkeypox belongs, and is currently being monitored and treated as a "presumptive positive" case until the CDC itself confirms the patient has monkeypox.
Another six people are being monitored for possible signs of monkeypox after they sat near an asymptomatic traveler while on a flight from Nigeria to the United Kingdom in early May.
Immediately following the confirmation of America's first positive case, the federal government, through the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services, reached out to Danish biotech company Bavarian Nordic to procure smallpox vaccines.
The vaccines will be freeze-dried to extend their shelf lives. Manufacturing will begin in 2023 and 2024.
The contract also includes the government option to purchase more smallpox vaccines valued at $180 million. If this second option is exercised, that will amount to approximately 13 million freeze-dried doses of the smallpox vaccines.
It should be noted that Fauci's NIAID gave about $100 million to Bavarian Nordic for research on smallpox vaccines in the early 2000s. This is around the same time the federal government first worked with Bavarian Nordic on the development, manufacturing and supply of smallpox vaccines for the United States.
To date, Bavarian Nordic has supplied the government with nearly 30 million doses of the liquid-frozen version of the smallpox vaccines, with the vast majority being delivered to the U.S. even before the Food and Drug Administration gave emergency use authorization for the vaccine in 2019.
Bavarian Nordic's modified smallpox vaccine was given emergency use authorization for use against monkeypox in September 2019, several months before the start of the Wuhan coronavirus (COVID-19) pandemic. (Related: US developing lethal, new genetically engineered viruses, including MOUSEPOX and MONKEYPOX… will these be used to demand MORE JABS in the name of "public safety?")
Fauci-backed Bavarian Nordic's stock, BVNRY, surged after it won large contracts for vaccines against monkeypox not just from the U.S. government but also from at least one other country in Europe.
Following Bavarian Nordic's press release that it has won these massive orders, BVNRY surged by more than 68 percent. Samuel O'Brient, a financial news writer for InvestorPlace, noted this is likely just the beginning of the company's new growth trajectory.
"Bavarian Nordic is in the unique position of being able to provide a product that the entire world may soon need. Countries are still dealing with rising COVID-19 cases, and another infectious disease is the last thing anyone needs. A rare virus vaccine from a little-known drug maker may be about to prevent the next public health crisis," O'Brient wrote.
"The COVID-19 vaccine rase ushered in a new biotech boom as investor focus shifted to the pharmaceutical sector. Wall Street may be about to see the same phenomenon play out as other biotech stocks rise on the momentum generated by a new vaccine champion."
For more news about Big Pharma profiting off disease outbreaks, head over to BigPharmaNews.com.
Watch this clip from "The American Journal" of InfoWars as host Harrison Hill Smith discusses the government's decision to purchase 13 million monkeypox vaccine doses.